Key Dates

Related Announcements

• October 31, 2023 - Notice of Special Interest (NOSI): Using Targeted Degradation of Protein and non-Protein Targets for the Development of Novel Anti-Infectives. See NOSI NOT-AI-23-076
• June 23, 2023 - Notice of Special Interest (NOSI): Using Targeted Degradation of Protein and non-Protein Targets for the Development of Novel Anti-Infectives.  See NOSI NOT-AI-23-049

Issued by

National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

The purpose of this Notice is to inform the extramural community that NOT-AI-23-049, “Notice of Special Interest (NOSI): Using Targeted Degradation of Protein and non-Protein Targets for the Development of Novel Anti-Infectives,” will be expired as of October 31, 2023. 

In place of NOT-AI-23-049, NIAID has issued NOT-AI-23-076, “Notice of Special Interest (NOSI): Using Targeted Degradation of Protein and non-Protein Targets for the Development of Novel Anti-Infectives;” this new NOSI retains the same aims and was expanded to include the development of anti-infective strategies against parasitic pathogens and/or their toxins. This new NOSI directs interested applicants to the following funding opportunity announcements:

• PA-20-185 – NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
• PA-20-195 – NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
• PA-20-200 – NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
• PA-23-232 – PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
• PA-23-230 – PHS 2023-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)

Inquiries

Please direct all inquiries to:

Raymond M. Slay, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 301-325-8578
Email: [email protected]